目次

1. Introduction to KRAS Inhibitors
1.1 Overview
1.2 Evolution of KRAS Inhibitors

2. KRAS Inhibitors - Mode of Action

3. Role of KRAS Inhibitors in Cancer Therapy

4. KRAS Inhibitors For Targeting Lung Cancer
4.1 Impact of KRAS Inhibitors on Lung Cancer
4.2 Ongoing Research and Development

5. KRAS Inhibitors in Pancreatic Cancer
5.1 Role of KRAS Inhibitors in Pancreatic Cancer
5.2 Recent Advancement in Pancreatic Cancer Targeting KRAS Inhibitors

6. KRAS Inhibitors for Colorectal Cancer
6.1 Potential of KRAS Inhibitors Against Colorectal Cancer
6.2 Ongoing Research and Development

7. KRAS inhibitors For Other Cancers
7.1 Potential of KRAS Inhibitors as Hematological Cancer Therapeutics
7.2 KRAS inhibitors in Prostate Cancer
7.3 KRAS Inhibitors for Gastric Cancer
7.4 KRAS Inhibition in Endometrium Cancer
7.5 Role of KRAS Inhibitors in Brain Cancer

8. Lumakras - 1st Approved KRAS Inhibitor
8.1 Overview and Patent Insight
8.2 Dosage and Price Analysis
8.3 Sales Analysis and Forecast Till 2028

9. Global KRAS Inhibitor Market Overview
9.1 Current Market Scenario
9.2 Future Market Opportunity

10. KRAS Inhibitor Market Regional Analysis - Based Upon Drug Approval
10.1 US
10.2 UK
10.3 China
10.4 Europe
10.5 Japan
10.6 South Korea
10.7 Canada

11. Global KRAS Inhibitors Clinical Trials Indicators
11.1 By Country
11.2 By Phase
11.3 By Company
11.4 By Indication
11.5 By Patient Segment

12. Global KRAS Inhibitors Clinical Pipeline By Company, Indication and Phase
12.1 Research
12.2 Preclinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-III
12.6 Preregistration

13. Marketed KRAS Inhibitors Clinical Insight

14. Global KRAS Inhibitors Market Dynamics
14.1 Driving Factors for KRAS Inhibitor Market
14.2 Challenges for KRAS Inhibitors Market

15. Competitive Landscape
15.1 Amgen
15.2 Mirati Therapeutics
15.3 Revolution Medicines
15.4 Boehringer Ingelheim
15.5 Merck
15.6 Moderna
15.7 Silenseed Ltd
15.8 Johnson and Johnson
15.9 Eli Lilly
15.10 Oblique Therapeutics
15.11 Cotinga Pharmaceuticals
15.12 Codiak Biosciences
15.13 Gilead

List of Figures & Tables
Figure 1-1: RAS Mutation - Frequency of KRAS Mutation v/s HRAS and NRAS Mutations
Figure 1-2: Historical Development of KRAS Inhibitors
Figure 2-1: General Mechanism of KRAS Inhibitors against Cancer
Figure 2-2: Targeting Approaches of KRAS Inhibitors
Figure 2-3: Direct Targeting of Mutant KRAS
Figure 2-4: Targets for Modifying the KRAS Membrane Association
Figure 3-1: KRAS Mutational Frequency by Organs (%)
Figure 3-2: Roles of KRAS Inhibitors in Cancer Treatment
Figure 4-1: Global - Newly Diagnosed Cases and Deaths related to Lung Cancer (Million), 2020
Figure 4-2: Global - Lung Cancer Incidence by Type (%), 2020
Figure 4-3: Impact of KRAS Inhibitor on Lung Cancer
Figure 4-4: Investigational KRAS Inhibitors for Lung Cancer
Figure 4-5: Codebreak 200 Trial - Study Initiation and Expected Completion Year
Figure 4-6: Codebreak 105 Trial - Study Initiation and Expected Completion Year
Figure 4-7: Codebreak 101 Trial - Study Initiation and Expected Completion Year
Figure 4-8: Krystal 7 trial - Study Initiation and Expected Completion Year
Figure 4-9: Krystal 1 trial - Study Initiation and Expected Completion Year
Figure 4-10: Krystal 2 trial - Study Initiation and Expected Completion Year
Figure 4-11: BI-1701963 Phase I Trial - Study Initiation and Expected Completion Year
Figure 4-12: mRNA-5671 Phase I Trial - Study Initiation and Expected Completion Year
Figure 4-13: Mechanism of BI-2852 against Lung Cancer
Figure 5-1: Global - Newly Diagnosed Cases and Deaths related to Pancreatic Cancer, 2020
Figure 5-2: Ideal Targets of Inhibiting KRAS Mutation of Pancreatic Cancer
Figure 5-3: Role of KRAS Inhibitors in Pancreatic Cancer
Figure 5-4: Investigational KRAS Inhibitors for Pancreatic Cancer
Figure 5-5: siG12D LODER Phase II Trial - Study Initiation and Expected Completion Year
Figure 5-6: iExosomes Phase I Trial - Study Initiation and Expected Completion Year
Figure 5-7: KRAS mTCR PBL Phase I/II Trial - Study Initiation and Expected Completion Year
Figure 6-1: Global - Newly Diagnosed Cases and Deaths related to Colon Cancer (Million), 2020
Figure 6-2: Global - Newly Diagnosed Cases and Deaths related to Rectum Cancer (Million), 2020
Figure 6-3: Ideal Targets for Inhibiting KRAS Mutation of Pancreatic Cancer
Figure 6-4: Investigational KRAS Inhibitors for Colorectal Cancer
Figure 7-1: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 7-2: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 7-3: Frequency of KRAS Mutation in Hematological Cancer (%)
Figure 7-4: Global - Newly Diagnosed Cases and Deaths related to Prostate Cancer (Million), 2020
Figure 7-5: Global - Number of Newly Diagnosed Gastric Cancer Cases and Deaths, 2020
Figure 7-6: Global - Number of Newly Diagnosed Cases of Endometrial Cancer by Type, 2020
Figure 7-7: Global - Number of Deaths of Endometrium Cancer by Type, 2020
Figure 7-8: Global - Newly Diagnosed Cases and Deaths related to Brain Cancer, 2020
Figure 8-1: Lumakras - Approval Year by Region
Figure 8-2: US - Lumakras Patent Expiration Year
Figure 8-3: US - Lumakras FDA Approval and Patent Exclusivity Year
Figure 8-4: US - Price for 240 Tablet Lumakras Supply and Price Per Unit of 120mg Tablet (US$), March’2022
Figure 8-5: UK - Price for 240 Tablet Lumakras Supply and Price Per Unit of 120mg Tablet (GBP/US$), March’2022
Figure 8-6: US - Monthly and Annual Treatment Cost with Lumakras (US$), March’2022
Figure 8-7: Lumakras - Recommended Initial and Reduced Dose (mg/day)
Figure 8-8: Global - Lumakras/Lumykras Annual Sales by Region (US$ Million), 2021
Figure 8-9: Global - Lumakras/Lumykras Annual Sales by Region (%), 2021
Figure 8-10: Global - Lumakras/Lumykras Quarterly Sales (US$ Million), Q2-Q4’2021
Figure 8-11: US - Lumakras/Lumykras Quarterly Sales (US$ Million), Q2-Q4’2021
Figure 8-12: ROW - Lumakras/Lumykras Quarterly Sales (US$ Million), Q3 and Q4’2021
Figure 8-13: Global - Lumakras Sales Forecast (US$ Million), 2022 - 2028
Figure 8-14: US - Lumakras Sales Forecast (US$ Million), 2022 - 2028
Figure 9-1: Global - Cancer Incidences and Deaths (Million), 2020
Figure 9-2: KRAS Inhibitor Market Size by Region (US$ Million), 2021
Figure 9-3: KRAS Inhibitor Market Size by Region (%), 2021
Figure 9-4: Global - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 9-5: KRAS Inhibitor Market Size by Product (%), 2028
Figure 10-1: US - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 10-2: US vs. ROW - KRAS Inhibitor Market Size (US$ Million), 2021
Figure 10-3: US vs. ROW - KRAS Inhibitor Market Size (%), 2021
Figure 10-4: US - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 10-5: UK - Cancer Incidences and Deaths, 2020 and 2025
Figure 10-6: UK vs. ROW - KRAS Inhibitor Market Size (US$ Million), 2021
Figure 10-7: UK vs. ROW - KRAS Inhibitor Market Size (%), 2021
Figure 10-8: UK - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 10-9: China - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 10-10: China - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 10-11: Europe - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 10-12: Europe - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 10-13: Japan - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 10-14: Japan - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 10-15: South Korea - Cancer Incidences and Deaths, 2020 and 2025
Figure 10-16: South Korea - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 10-17: Canada - Cancer Incidences and Deaths, 2020 and 2025
Figure 10-18: Canada vs. ROW - KRAS Inhibitor Market Size (US$ Million), 2021
Figure 10-19: Canada vs. ROW - KRAS Inhibitor Market Size (%), 2021
Figure 10-20: Canada - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
Figure 11-1: Global - KRAS Protein inhibitors Clinical Trials by Country, 2022 -2028
Figure 11-2: Global - KRAS Protein inhibitors Clinical Trials by Phase, 2022 -2028
Figure 11-3: Global - KRAS Protein inhibitors Clinical Trials by Company, 2022 -2028
Figure 11- 4: Global - KRAS Protein inhibitors Clinical Trials by Indication, 2022 -2028
Figure 11-5: Global - KRAS Protein inhibitors Clinical Trials by Patient Segment, 2022 -2028
Figure 14-1: Drivers for KRAS Inhibitor Market
Figure 14-2: Challenges for KRAS Inhibitor Market
Figure 14-3: Global - Estimated Monthly Treatment Cost of AMG 150 v/s Other Cell Signal Targeting Therapeutics